Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.

Abstract

Ebola virus is one of the most threatening pathogens with the mortality rate as high as 90% in the world. There are no licensed therapeutic drugs or preventive vaccines for Ebola hemorrhagic fever up to date. Favipiravir, a novel antiviral drug which was mainly used for the treatment of influenza, now has been demonstrated to have a curative effect in treating Ebola virus infection. In this review, we present an overview of recent progress on the treatment of Ebola virus disease with Favipiravir and describe its possible mechanism. Moreover, we give a brief summary of other related treatment strategies against Ebola.

• Authors: Tao Zhang, Min Zhai, Jianbo Ji, Jian Zhang, Ye Tian, Xinyong Liu
• Journal: Bioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 27 Issue 11 Pg. 2364-2368 (06 01 2017) ISSN: 1464-3405 [Electronic] England
• PMID: 28462833 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2017 Elsevier Ltd. All rights reserved.

Chemical References

• Amides
• Antiviral Agents
• Pyrazines
• favipiravir

Topics

• Amides (therapeutic use)
• Animals
• Antiviral Agents (therapeutic use)
• Hemorrhagic Fever, Ebola (drug therapy)
• Humans
• Mice
• Pyrazines (therapeutic use)